Maa: Armenia
Kieli: englanti
Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
metformin (metformin hydrochloride)
Morningside Pharmaceuticals Ltd
metformin (metformin hydrochloride)
1000mg
tablets prolonged-release
Prescription
PACKAGE LEAFLET: INFORMATION FOR THE USER Metabet SR 1000 mg Prolonged Release Tablets Metformin hydrochloride This medicine is intended for ADULT patients only. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Metabet SR is and what it is used for 2. What you need to know before you take Metabet SR 3. How to take Metabet SR 4. Possible side effects 5. How to store Metabet SR 6. Contents of the pack and other information Metabet SR 1000mg prolonged release tablets contain the active ingredient metformin hydrochloride and belongs to a group of medicines called biguanides which are used in the treatment of diabetes. Metabet SR is used for the treatment of Type 2 (non-insulin dependent) diabetes mellitus when diet and exercise changes alone have not been enough to control blood glucose (sugar). Insulin is a hormone that enables body tissues to take glucose from the blood and use it for energy or for storage for future use. People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a build-up of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms. Metabet SR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose. Metabet SR is associated with either a stable body weight or modest weight loss. Metabet SR prolonged release tablets are specia Lue koko asiakirja
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metabet SR 1000 mg prolonged release tablets Bolamyn SR 1000 mg prolonged release tablets Metformin 1000 mg prolonged release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release tablet contains: Metformin hydrochloride 1000 mg corresponding to 780 mg metformin base For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged release tablet . Off-white coloured, oval, biconvex, film-coated tablets with score line on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control. Metabet SR / Bolamyn SR / Metformin may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY ADULTS WITH NORMAL RENAL FUNCTION (GFR ≥ 90 ML/MIN): _Monotherapy and combination with other oral antidiabetic agents _ The usual starting dose is one tablet of Metabet SR / Bolamyn SR / Metformin 500 mg tablet once daily. After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 2 tablets of Metabet SR / Bolamyn SR / Metformin 1000 mg tablet daily. Dosage increases should be made in increments of 500 mg every 10-15 days, up to a maximum of 2000 mg once daily with the evening meal. If glycaemic control is not achieved on 2000 mg of Metabet SR / Bolamyn SR / Metformin once daily, 1000 mg of Metabet SR / Bolamyn SR / Metformin twice daily should be considered, with both doses being given with food. If glycaemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily. In patients already treated with metformin tablets, the starting dose of Metabet SR / Bolamyn SR Lue koko asiakirja